Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 7/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 6/20 | 0.52 |
| ▸ | KDR | P35968 | 10/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17996103 | 0.93 | DNMT3A (0.52) | DNMT3ADNMT1KDRAURKACDK1 | |
| SCHEMBL17996102 | 0.93 | DNMT3A (0.60) | DNMT3ADNMT1KDRAURKA | |
| SCHEMBL17996119 | 0.92 | DNMT3A (0.51) | DNMT3ADNMT1KDRAURKACDK1 | |
| SCHEMBL17996117 | 0.91 | DNMT3A (0.49) | DNMT3ADNMT1KDRAURKACHEK2 | |
| SCHEMBL17996085 | 0.89 | DNMT3A (0.49) | DNMT3ADNMT1KDRAURKA | |
| SCHEMBL17996101 | 0.88 | DNMT3A (0.51) | DNMT3ADNMT1KDRAURKACDK1 | |
| SCHEMBL16596215 | 0.88 | DNMT3A (0.61) | DNMT3ADNMT1KDRAURKACDK1 | |
| SCHEMBL17996083 | 0.85 | DNMT3A (0.48) | DNMT3ADNMT1KDRAURKACDK1 | |
| SCHEMBL16596259 | 0.85 | DNMT1 (0.59) | DNMT3ADNMT1KDRAURKACDK1 | |
| SCHEMBL17996124 | 0.83 | DNMT3A (0.58) | DNMT3ADNMT1KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046917-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PF MEDICAMENT (FR) | 2017-11-08 | — | — | EP | disclosed |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-08-11 | — | — | US | disclosed |
| WO-2015040169-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2015-03-26 | — | — | WO | disclosed |
| US-8952016-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | DNMT1, DNMT3A, TPMT | DNMT3A 2/4885DNMT1 1/4885KDR 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.